Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 6 | 2023 | 131 | 0.930 |
Why?
|
| Community Health Centers | 3 | 2013 | 98 | 0.720 |
Why?
|
| Public Health | 2 | 2013 | 188 | 0.650 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2007 | 214 | 0.600 |
Why?
|
| Exercise | 4 | 2013 | 970 | 0.550 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2013 | 235 | 0.540 |
Why?
|
| Telemedicine | 1 | 2023 | 379 | 0.540 |
Why?
|
| Anticoagulants | 5 | 2020 | 529 | 0.530 |
Why?
|
| Medicare Part D | 1 | 2017 | 36 | 0.520 |
Why?
|
| Cost Savings | 1 | 2017 | 60 | 0.510 |
Why?
|
| Primary Health Care | 2 | 2013 | 726 | 0.490 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 735 | 0.470 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 75 | 0.460 |
Why?
|
| Polypharmacy | 1 | 2016 | 67 | 0.460 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 25 | 0.450 |
Why?
|
| Aspirin | 2 | 2013 | 172 | 0.450 |
Why?
|
| Pancreatitis | 1 | 2016 | 96 | 0.450 |
Why?
|
| Ticlopidine | 3 | 2013 | 47 | 0.400 |
Why?
|
| Venous Thromboembolism | 4 | 2020 | 154 | 0.400 |
Why?
|
| Warfarin | 2 | 2014 | 125 | 0.390 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 308 | 0.390 |
Why?
|
| Stroke | 3 | 2013 | 1226 | 0.290 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 35 | 0.250 |
Why?
|
| Hemorrhage | 6 | 2018 | 287 | 0.240 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2006 | 171 | 0.220 |
Why?
|
| Humans | 26 | 2023 | 65872 | 0.210 |
Why?
|
| Angina, Unstable | 1 | 2004 | 56 | 0.210 |
Why?
|
| Coronary Disease | 1 | 2006 | 247 | 0.210 |
Why?
|
| Tyrosine | 1 | 2004 | 93 | 0.210 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 885 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2018 | 812 | 0.210 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2023 | 3 | 0.200 |
Why?
|
| Anemia, Hemolytic | 1 | 2023 | 13 | 0.200 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 171 | 0.200 |
Why?
|
| Quinolones | 1 | 2023 | 25 | 0.200 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2003 | 21 | 0.190 |
Why?
|
| Computers, Handheld | 1 | 2003 | 37 | 0.190 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 65 | 0.190 |
Why?
|
| Coronary Artery Disease | 3 | 2016 | 326 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 95 | 0.180 |
Why?
|
| Urban Population | 1 | 2023 | 201 | 0.180 |
Why?
|
| Documentation | 1 | 2003 | 135 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 558 | 0.160 |
Why?
|
| Pharmaceutical Services | 2 | 2017 | 33 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 691 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6956 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 175 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 922 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 463 | 0.130 |
Why?
|
| Pharmacies | 1 | 2017 | 36 | 0.130 |
Why?
|
| Rivaroxaban | 2 | 2014 | 19 | 0.120 |
Why?
|
| Dabigatran | 2 | 2014 | 20 | 0.120 |
Why?
|
| Male | 11 | 2020 | 31435 | 0.120 |
Why?
|
| Pyridones | 2 | 2014 | 43 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2014 | 88 | 0.120 |
Why?
|
| Hospitalization | 3 | 2020 | 1404 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 489 | 0.120 |
Why?
|
| Benzazepines | 1 | 2016 | 21 | 0.120 |
Why?
|
| Female | 11 | 2020 | 34459 | 0.120 |
Why?
|
| Massachusetts | 3 | 2017 | 2161 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 197 | 0.110 |
Why?
|
| Adult | 7 | 2023 | 17595 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 171 | 0.100 |
Why?
|
| Aged | 6 | 2017 | 15155 | 0.100 |
Why?
|
| Dipyridamole | 1 | 2013 | 17 | 0.100 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 9 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2013 | 8 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2016 | 279 | 0.100 |
Why?
|
| Thiophenes | 1 | 2013 | 31 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 462 | 0.100 |
Why?
|
| Morpholines | 1 | 2013 | 91 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 55 | 0.090 |
Why?
|
| Proline | 1 | 2013 | 46 | 0.090 |
Why?
|
| Fees and Charges | 1 | 2012 | 17 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2013 | 165 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2013 | 135 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5832 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 89 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 109 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 2011 | 8 | 0.090 |
Why?
|
| Students, Pharmacy | 1 | 2011 | 12 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 104 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2013 | 749 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1165 | 0.080 |
Why?
|
| Middle Aged | 7 | 2016 | 18518 | 0.080 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 69 | 0.080 |
Why?
|
| Community Health Services | 1 | 2012 | 127 | 0.080 |
Why?
|
| Motor Activity | 1 | 2012 | 347 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 995 | 0.070 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2009 | 4 | 0.070 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2009 | 3 | 0.070 |
Why?
|
| Medical Waste Disposal | 1 | 2009 | 4 | 0.070 |
Why?
|
| Risk Factors | 3 | 2013 | 5477 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1595 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2016 | 827 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 103 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 208 | 0.070 |
Why?
|
| Health Promotion | 1 | 2012 | 524 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 4887 | 0.070 |
Why?
|
| Adolescent | 2 | 2016 | 6371 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 230 | 0.060 |
Why?
|
| Child | 1 | 2016 | 4656 | 0.060 |
Why?
|
| United States | 2 | 2017 | 8192 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 253 | 0.060 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 23 | 0.060 |
Why?
|
| Poverty | 1 | 2008 | 307 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 183 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 296 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 859 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 33 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2004 | 106 | 0.050 |
Why?
|
| Acute Disease | 1 | 2006 | 665 | 0.050 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2023 | 3 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 770 | 0.050 |
Why?
|
| Pyruvate Kinase | 1 | 2023 | 11 | 0.050 |
Why?
|
| Hemolysis | 1 | 2023 | 41 | 0.050 |
Why?
|
| Quinolines | 1 | 2023 | 47 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2006 | 310 | 0.050 |
Why?
|
| Piperazines | 1 | 2023 | 86 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2003 | 41 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2011 | 3340 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 589 | 0.050 |
Why?
|
| Incidence | 1 | 2006 | 1434 | 0.040 |
Why?
|
| Registries | 1 | 2006 | 935 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 740 | 0.040 |
Why?
|
| Peptides | 1 | 2004 | 593 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 875 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 878 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 105 | 0.040 |
Why?
|
| Premedication | 1 | 2018 | 20 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 523 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 152 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 335 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 370 | 0.020 |
Why?
|
| Ribavirin | 1 | 2013 | 22 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 27 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 49 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2013 | 101 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 36 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2013 | 134 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 172 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 710 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 154 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 309 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2009 | 6 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 24 | 0.020 |
Why?
|
| Environmental Pollution | 1 | 2009 | 14 | 0.020 |
Why?
|
| Training Support | 1 | 2009 | 20 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 41 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 159 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2011 | 398 | 0.020 |
Why?
|
| Community Participation | 1 | 2008 | 48 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 27 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 968 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 126 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 384 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 604 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 204 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 757 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 2653 | 0.010 |
Why?
|
| Thrombosis | 1 | 2007 | 207 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 198 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 638 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 5684 | 0.010 |
Why?
|